Latest Business and People News
Updated employee announcements, business news, awards, and recognition in the industry today.
People News
Saama Technologies, Inc., a big data and analytics solutions company, announced that Mehdi Benchoufi, M.D., Assistant Professor in the Clinical Epidemiology Center at Hôtel-Dieu Hospital, University Paris Descartes, has joined its Board of Advisors.
Bio-Optronics, the maker of the Clinical Conductor Clinical Trial Management System, announces the appointment of Sujay Jadhav to its Board of Directors.
LabConnect, LLC, a global provider of central laboratory and support services for biopharmaceutical, medical device, and CROs, announces the promotion of three executives to top-level management positions: Barry Simms, MBA, as Chief Operating Officer, Trenton Harris, MSM/MBA, as Executive Vice President and Elizabeth Koury, MS, as Vice President, scientific affairs.
Clinipace, a global full-service CRO, expands its leadership team by appointing Dawn Sauro as Chief Development Officer and Sharon Moore as Chief Medical Officer.
InClinica, a global clinical CRO, announced that Jeffrey Schwartz has been appointed Assistant Vice President of Business Development and Anthony J. Esposito, Jr. has been appointed Senior Director of Quality Assurance.
Business News
Veeva Systems, a cloud-based solutions provider, announced that 12 adapters including a top 20 pharmaceutical company and CROs are now using Veeva Vault EDC to improve data management in their clinical trials.
Novotech, an Asia-Pacific CRO, announced that it has signed Memorandum of Understandings with five medical institutions in the region.
Clinipace, a global full-service CRO, expands its leadership team and launches a new brand identity, CHALLENGE ACCEPTED, to support its future growth as a midsized CRO.
proinnovera GmbH, a full service CRO, announced the establishment of the Company’s wholly owned subsidiary, proinnovera Inc. in North Carolina.
Recognition
Certara, a drug development consultancy, served as a key member of the MDGH drug development team when they were granted FDA approval for moxidectin for river blindness.
Navitas Life Sciences, a full service Clinical, Regulatory & Safety solutions and services provider, announced that it has been recognized as a ‘Leader’ in the IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
